The Food and Drug Administration yesterday updated its Risk Evaluation and Mitigation Strategy for extended-release and long-acting opioid analgesics, and extended the same requirements to immediate-release opioid analgesic products. The REMS applies to 347 opioid analgesics intended for outpatient use. Among other changes, the updates modify the prescriber education blueprint to include more information on pain management and require manufacturers to make training available to other, non-physician prescribers, such as nurses and pharmacists involved in pain management. FDA announced the planned updates last year. In other news, the Centers for Disease Control and Prevention recently released a resource to help health care providers implement its guidelines for prescribing opioids for chronic pain.

Related News Articles

Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…
Headline
While counseling and other services are an important part of a comprehensive treatment plan for opioid use disorder, the provision of medication should not be…
Headline
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic…
Headline
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and…